Long-term effects of bezafibrate on in vivo VLDL-triglyceride production in the rat.
Long-term effects of bezafibrate on in vivo production of VLDL-triglyceride were studied in the rat. Bezafibrate given at a daily dose of 30 mg/kg body weight for 14 days produced a decrease not only in triglyceride by 51% but in cholesterol by 28% and phospholipid by 18%. Despite a marked reduction in plasma triglyceride concentrations, there was no significant change in the rate of VLDL-triglyceride secretion from the liver into the circulation between bezafibrate-treated and control animals (1113 +/- 58 and 1234 +/- 63 micrograms/min, respectively). In addition, bezafibrate produced no change in lipid composition in VLDL. These results suggest that bezafibrate enhances triglyceride removal from the circulation, which leads to reduction in plasma triglyceride.
Kazumi
T
T
Department of Medicine, Hyogo Medical Center for Adults, Akashi, Japan.
Yoshino
G
G
Iwai
M
M
Matsuba
K
K
Matsushita
M
M
Iwatani
I
I
Kasama
T
T
Yoshida
M
M
Baba
S
S
D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003902:Detergents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D008079:Lipoproteins, VLDL / Q000096:biosynthesis*; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D010743:Phospholipids / Q000097:blood; D011092:Polyethylene Glycols / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D014280:Triglycerides / Q000096:biosynthesis* / Q000097:blood
D001786:Blood Glucose; D008076:Cholesterol, HDL; D003902:Detergents; D007328:Insulin; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D011092:Polyethylene Glycols; D002784:Cholesterol; C016811:tyloxapol; D001629:Bezafibrate